SynthesisWorld journal of pediatrics : WJP2023
Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis.
Synthesis in World journal of pediatrics : WJP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Synergistic properties of linezolid against Enterococcus spp. isolates: a systematic review from in vitro studies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Pooled it
- Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.European journal of clinical pharmacology · 2023Pooled it
- Linezolid and vancomycin for nosocomial infections in pediatric patients: a systematic review.Jornal de pediatriaPooled it
- Lactate abnormalities during intravenous linezolid therapy in hospitalized children: a brief report.European journal of pediatrics · 2026Article
- Clindamycin and intravenous immunoglobulins in pediatric invasive group A streptococcal disease: what is the evidence?European journal of pediatrics · 2026Review
- Piperacillin-tazobactam-associated thrombocytopenia with negative antiplatelet antibody testing: a case report and literature review.Frontiers in medicine · 2026Article
- Evolving treatment strategies for invasive Streptococcus pyogenes in children in the postpandemic era.Clinical and experimental pediatrics · 2025Article
- Clinical use and safety profile of intravenous linezolid in hospitalised children: A retrospective cohort experience.European journal of pediatrics · 2025Article
- Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.Antimicrobial agents and chemotherapy · 2025Article
- Linezolid in the Focus of Antimicrobial Resistance ofInternational journal of molecular sciences · 2025Review
- Population pharmacokinetics and clinical assessment of linezolid in pediatric bacterial infections.Antimicrobial agents and chemotherapy · 2025Article
- Evaluation of pharmacokinetic target attainment and hematological toxicity of linezolid in pediatric patients.European journal of clinical pharmacology · 2024Observational
- Assessment of Antibiotic Resistance in Pediatric Infections: A Romanian Case Study on Pathogen Prevalence and Effective Treatments.Antibiotics (Basel, Switzerland) · 2024Article
- Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.Frontiers in pharmacology · 2024Article
- Compassionate use of contezolid in a toddler with severe community-acquired pneumonia induced by staphylococcus aureus: a case report and follow-up.Frontiers in pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWe aimed to evaluate the tolerability and efficacy of linezolid in children for treating suspected and diagnosed Gram-positive bacterial infections.
methodsA systematic literature search was conducted up to April 23, 2021, using linezolid and its synonyms as search terms. Two reviewers independently identified and extracted relevant randomized controlled trials and prospective cohort studies. The extracted studies were included in a single-rate meta-analysis of adverse events and clinical outcomes using random-effects models.
resultsA total of 1082 articles were identified, and nine studies involving 758 children were included in the meta-analysis. The overall proportion of adverse events was 8.91% [95% confidence interval (CI) = 1.64%-36.52%], with diarrhea (2.24%), vomiting (2.05%), and rash (1.72%) being the most common. The incidences of thrombocytopenia and anemia were 0.68% and 0.16%, respectively. Some specific adverse events, including rash and gastrointestinal events, were more frequent in the oral administration subgroup. In terms of efficacy, the overall proportion of clinical improvement was 88.80% (95% CI = 81.31%-93.52%). Children with a history of specific bacteriological diagnosis or concomitant antibiotic therapy had a 1.13-fold higher clinical improvement than children without such histories. The proportion of microbial eradication was 92.68% (95% CI = 84.66%-96.68%). The proportion of all-cause mortality was 0.16% (95% CI = 0.00%-7.75%).
conclusionsLinezolid was well-tolerated in pediatric patients and was associated with a low frequency of adverse events, such as anemia, thrombocytopenia, and neutropenia. Moreover, linezolid was effective in children with diagnosed and suspected Gram-positive infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.